55580-00-2

Upstream product

• 55579-99-2 4-(4-Methoxyphenoxy)butyric Acid 
• 150-76-5 4-methoxy-phenol 
• 337913-25-4 phosphorus pentaoxide 
• 20744-05-2 4-(4-methoxyphenoxy)butyric acid ethyl ester 

Downstream Products

• 1027971-80-7 7-Methoxy-4-[1-(4-methoxy-phenyl)-meth-(E)-ylidene]-3,4-dihydro-2H-benzo[b]oxepin-5-one 
• 1206525-08-7 C₂₂H₁₇NO₃ 
• 1206525-02-1 C₂₇H₂₆N₂O₂ 
• 1206525-04-3 C₃₁H₂₅ClN₂O₂ 
• 1384168-45-9 C₂₂H₁₇N₃O₄ 
• 1027391-76-9 7-Methoxy-4-[1-(4-methoxy-phenyl)-meth-(E)-ylidene]-2,3,4,5-tetrahydro-benzo[b]oxepin-5-ol 

Relevant academic research and scientific papers

Discovery and SAR of potent, orally available and brain-penetrable 5,6-dihydro-4H-3-thia-1-aza-benzo[e]azulen- and 4,5-dihydro-6-oxa-3-thia-1-aza- benzo[e]azulen derivatives as neuropeptide Y Y5 receptor antagonists

Combination of structural elements from a potent Y5 antagonist (2) with thiazole fragments that exhibit weak Y5 affinities followed by lead optimisation led to the discovery of (5,6-dihydro-4H-3-thia-1-aza-benzo[e]azulen-2-yl)- piperidin-4-ylmethyl-amino and (4,5-dihydro-6-oxa-3-thia-1-aza-benzo[e]azulen-2- yl)-piperidin-4-ylmethyl-amino derivatives. Both classes of compounds are capable of delivering potent and selective orally and centrally bioavailable NPY Y5 receptor antagonists.

Conformationally Restricted Tetrahydro-1-benzoxepin Analogs of Hallucinogenic Phenethylamines

Tetrahydro-1-benzoxepin analogs of prototypical 4-substituted-2,5-dimethoxyphenylisopropylamines were prepared as agents having restricted conformational mobility in the 2-alkoxy group and alkylamine sidechain. The derivatives were evaluated for their abi

Substituted tetralins, chromans and related compounds in the treatment of asthma, arthritis and related diseases

Substituted tetralins, chromans and related compounds which, by inhibiting 5-lipoxygenase enzyme and/or blocking leukotriene receptors, are useful in the prevention or treatment of asthma, arthritis, psoriasis, ulcers, myocardial infarction and related disease states in mammals, pharmaceutical compositions thereof, a method of treatment therewith, and to intermediates useful in the synthesis thereof.

A New Class of Antiarrhythmic Agents: Mannich Bases of 3,4-Dihydro-1-benzoxepin-5(2H)-ones and Related Compounds

Mannich bases derived from 3,4-dihydro-1-benzoxepin-5(2H)-ones, chromanones and 6,7,8,9-tetrahydrobenzocyclohepten-5(H)-one have been synthesised and shown to possess marked antiarrhythmic activity; 3,4-dihydro-7-methyl-4-(1-piperidinomethyl)- and 3,4-dih

Ethers of 3,4-dihydro-1-benzoxepin-5-one oxime to treat intestinal disorders

Therapeutic compositions, particularly for treating intestinal disorders, and a method of treating colopathics by administering an effective amount of the compositions are described. The compositions contain a therapeutically effective amount of at least one isomer of the oximino group of the compound having the formula: STR1 in which: R is selected from the group consisting of halogen atoms and lower alkoxy groups; n is an integer 2 or 3, and Z1 and Z2 are the same or different lower alkyl groups, or NZ1 Z2 represents a saturated heterocyclic group which may have a second heteroatom selected from the group consisting of N and O, and the addition salts of the amino group with pharmaceutically acceptable acids, with a physiological acceptable excipient.